Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jul 12 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-2.09 Insider Own21.83% Shs Outstand43.55M Perf Week18.04%
Market Cap356.28M Forward P/E- EPS next Y-1.34 Insider Trans0.00% Shs Float41.32M Perf Month-20.80%
Income-96.80M PEG- EPS next Q-0.28 Inst Own65.23% Short Float1.47% Perf Quarter-13.59%
Sales14.81M P/S24.06 EPS this Y11.87% Inst Trans-0.39% Short Ratio1.65 Perf Half Y14.43%
Book/sh2.82 P/B2.39 EPS next Y-11.94% ROA-46.72% Short Interest0.61M Perf Year203.60%
Cash/sh3.08 P/C2.19 EPS next 5Y- ROE-96.32% 52W Range1.93 - 9.69 Perf YTD15.61%
Dividend Est.- P/FCF- EPS past 5Y-23.71% ROI-47.31% 52W High-30.44% Beta0.84
Dividend TTM- Quick Ratio5.23 Sales past 5Y230.91% Gross Margin65.46% 52W Low249.22% ATR (14)0.60
Dividend Ex-Date- Current Ratio5.23 EPS Y/Y TTM23.85% Oper. Margin-689.23% RSI (14)48.48 Volatility7.37% 10.37%
Employees154 Debt/Eq0.75 Sales Y/Y TTM-14.47% Profit Margin-653.50% Recom1.14 Target Price12.33
Option/ShortNo / Yes LT Debt/Eq0.66 EPS Q/Q- Payout- Rel Volume0.63 Prev Close6.83
Sales Surprise-84.91% EPS Surprise-23.46% Sales Q/Q-91.68% EarningsMay 13 BMO Avg Volume368.19K Price6.74
SMA201.08% SMA50-13.72% SMA2009.64% Trades Volume230,992 Change-1.32%
Date Action Analyst Rating Change Price Target Change
May-16-24Initiated BTIG Research Buy $12
May-13-24Initiated Needham Buy $11
Jun-22-23Initiated Wedbush Outperform $8
Jun-14-24 07:00AM
May-30-24 07:00AM
May-29-24 07:00AM
May-28-24 01:24PM
May-13-24 01:53PM
08:15AM Loading…
May-09-24 07:00AM
May-01-24 10:01AM
Apr-24-24 04:05PM
Apr-22-24 05:01PM
Apr-19-24 10:05AM
Apr-17-24 12:30AM
04:25PM Loading…
Apr-16-24 04:25PM
Apr-08-24 08:00AM
Apr-02-24 07:00AM
Mar-17-24 02:58PM
Mar-07-24 01:44PM
Mar-06-24 01:51PM
Feb-28-24 07:00AM
Feb-26-24 07:00AM
Feb-19-24 05:49AM
Feb-14-24 07:00AM
Feb-06-24 07:00AM
Jan-29-24 07:00AM
07:00AM Loading…
Jan-18-24 07:00AM
Jan-04-24 07:00AM
Dec-09-23 12:00PM
Dec-07-23 07:00AM
Dec-06-23 08:50AM
Dec-04-23 04:05PM
Dec-01-23 09:55AM
Nov-30-23 07:00AM
Nov-27-23 12:00PM
Nov-20-23 08:50AM
Nov-15-23 12:00PM
Nov-09-23 08:25AM
Nov-06-23 07:00AM
Nov-02-23 09:05AM
Oct-12-23 12:00PM
Sep-27-23 09:06AM
Sep-12-23 08:00AM
Sep-05-23 07:00AM
Aug-29-23 07:00AM
Aug-16-23 12:00PM
Aug-10-23 08:25AM
Jul-13-23 07:25AM
Jun-29-23 07:00AM
Jun-15-23 07:42AM
Jun-06-23 07:00AM
Jun-01-23 04:10PM
May-26-23 12:37AM
May-25-23 04:06PM
May-24-23 04:13PM
May-17-23 04:35PM
May-11-23 07:33AM
May-10-23 08:15AM
May-09-23 01:29PM
May-02-23 04:42PM
Apr-10-23 07:00AM
Mar-31-23 08:00AM
Mar-14-23 07:00AM
Mar-13-23 04:05PM
Mar-10-23 05:12AM
Mar-08-23 07:00AM
Mar-01-23 07:00AM
Feb-21-23 07:00AM
Jan-23-23 07:00AM
Jan-20-23 05:35AM
Jan-05-23 07:00AM
Dec-12-22 07:00AM
Dec-09-22 06:09AM
Dec-01-22 08:00AM
Nov-22-22 07:00AM
Nov-11-22 07:00AM
Nov-09-22 07:00AM
Nov-07-22 07:00AM
Nov-03-22 09:34AM
Oct-05-22 08:33AM
Sep-28-22 09:21AM
Sep-22-22 07:00AM
Sep-12-22 07:00AM
Sep-07-22 07:00AM
Aug-13-22 08:14AM
Aug-12-22 06:08AM
Aug-10-22 07:00AM
TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BARBERICH TIMOTHY JDirectorDec 19 '23Buy4.973171,57567,027Dec 21 05:00 PM
BARBERICH TIMOTHY JDirectorDec 18 '23Buy4.8928,830140,88166,710Dec 21 05:00 PM
Klencke BarbaraDirectorDec 14 '23Buy5.085,00025,40030,000Dec 18 06:01 PM